DOCSLIB.ORG

Chronic Pain: an Overview of Mechanisms and Management

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chronic Pain: an Overview of Mechanisms and Management Chronic Pain: an overview of mechanisms and management Dr Helen Cohen Consultant Rheumatology & Chronic Pain Royal National Orthopaedic Hospital Overview ∗ How pain works ∗ Pain mechanisms ∗ Guidelines ∗ Pharmacologic treatment ∗ Interventional treatment ∗ Pain management & rehabilitation ∗ Multiple types of pain ∗ Evolutionary survival system Nociception ∗ Primary afferent small myelinated A-δ and unmyelinated C-fibre nociceptors ∗ Transmit impulses to the dorsal horn of the spinal cord. ∗ A- δ terminate primarily on neurones in laminas I, V and X ∗ C-fibres terminate in laminas I – V (mainly I and II). ∗ C-fibres transmit to spinal second order interneurones ∗ wide dynamic range (WDR) respond to pain & touch ∗ nociceptive specific neurones Ascending tracts Nociceptive impulses ascend by two main pathways: ∗ The more modern neospinothalamic anterolateral system ∗ A-delta fibres ∗ Pain & non-painful temperature ∗ connects to spinothalamic tracts; pass to the lateral thalamus ∗ connections to the sensory cortex allowing the localisation of pain ∗ Discriminative pain – quality, intensity, location; ‘fast pain’ ∗ The primitive spino-reticulo-diencephalic tract in the posterolateral cord ∗ c-fibres ∗ connects to reticular system of the brainstem ∗ other connections to the thalamus and hypothalamus ∗ Affective/arousal/emotional aspects of pain; ‘slow pain’ ∗ Sympathetic outflow connections Descending control ∗ Periaqueductral gray-rostral ventromedial medulla (PAG-RVM) system ∗ Dorsal reticular nucleus (DRt) and ventrolateral medulla (VLM). ∗ Nucleus raphe magnus (NRM) and locus coeruleus in the pons ∗ These systems can be inhibitory or facilitatory ∗ Deficits of descending inhibition may be operating in some chronic pain syndromes eg. fibromyalgia ∗ Many different neurotransmitters ∗ Serotonin ∗ Noradrenaline Nociceptive neurotransmission ∗ Primary afferent neurones: ∗ Glutamate ∗ Other excitatory neuropeptides include calcitonin gene related peptide (cGRP) and substance P (SP), & many more ∗ Glutamate binds to NMDA and AMPA receptors ∗ GABA-ergic inhibitory neurones throughout spinal cord ∗ also activated by glycine ∗ Opiate receptors ∗ Nociceptive ion channels TRVP1, NaV1.7 – expressed in DRG and nociceptive cells ∗ Nerve growth factor – activation & sensitization of nociceptors ∗ Cannabinoid receptors – CB1, CB2 ∗ Endocannabinoids – inc. anadamide; degraded by FAA(fatty acid amide hydrolase) Central Processing ∗ Chronic pain as a network dysfunction ∗ No single ‘pain centre’ ∗ Many brain areas can be activated including: thalamus, reticular system, hypothalamus, periaqueductal grey, S1, S2 and cingulate cortex ∗ Thalamic connections to many cortical areas including limbic and anterior cingulate mediate the affective/emotional aspects of pain. ∗ Autonomic connections Peripheral sensitisation Nociceptors ∗ reduction in threshold ∗ increase in responsiveness ∗ Previously ‘silent’ c-fibres become active ∗ Nociceptor & ion channel modulation; changes in gene expression Central sensitisation ∗ Central sensitization is an increase in the excitability of neurons within the central nervous system, so that normal inputs begin to produce abnormal responses. ∗ WDR spinal neurones: ∗ increased excitability, ∗ decreased thresholds, ∗ widened receptive field ∗ Neuronal synaptic plasticity ∗ Enhanced presynaptic neurotransmitter release, recruitment of post synaptic NMDA receptors; changes in microglia, astrocytes, gap junctions, membrane excitability and gene transcription ‘Centralised’ pain Central Sensitization in Chronic Pain Pain itself can change how pain works, resulting in more pain with less provocation Neuroplasticity ∗ The process in which the brain's neural synapses and pathways are altered as an effect of environmental, behavioral, and neural changes ∗ Can be observed at multiple scales, from microscopic changes in individual neurons to larger-scale changes such as cortical remapping ∗ Maladaptive neuroplasticity in chronic pain conditions eg. phantom limb pain, CRPS Kumbhare DA, Elzibak AH, Noseworthy MD. Evaluation of Chronic Pain Using Magnetic Resonance (MR) Neuroimaging Approaches: What the Clinician Needs to Know. Clin J Pain. 2017 Apr;33(4):281-290. Kuner R, Flor H. Structural plasticity and reorganisation in chronic pain. Nat Rev Neurosci. 2016 Dec 15;18(1):20-30. Cortical Representation Somatotopic maps S1,S2, & beyond Face or hand, not both: perceptual correlates of reafferentation in a former amputee ∗ Article in Current Biology 12(15):1342-6 · September 2002 Farnè A1, Roy AC, Giraux P, Dubernard JM, Sirigu A. Cortical remapping following hand amputation and 5 months post transplantation. Changes in cortical reorganisation in PLP after training in sensory discrimination Hand Mouth Post training. Representation of the mouth moves to a more inferior lateral position Pre-training. Representation of the mouth invades the hand area Neuromagnetic source imaging Flor H; The Lancet Neurology 2002 Pain & genetics Pain plus syndromes ∗ Gain of function: SCN9/Na1.7 channel ∗ Primary erythromelalgia ∗ Paroxsysmal extreme pain disorder ∗ Familial hemiplegic migraine – loss & gain mutations in different genes Congenital Insensitivity to Pain syndromes ∗ SCN9 mutation / Nav1.7 channelopathy ∗ FAA-OUT – mutation impairing FAA – increased endocannabinoids Other ∗ COMT (Catechol-O-methyltransferase) – catecholamines have a role in pain processing/perception; COMT degrades dopamine, nor-adrenaline and adrenaline – effect on pain & modulation of opioidergic activity ∗ OPRM1 (mu opioid receptor) – impaired opioid response ∗ Pain is both a sensation And ∗ A perception ∗ This can dramatically change behavioural and emotional responses to pain Psychological factors ∗ Increased anxiety and depression ∗ Also attention deficit (and hyperactivity) disorder, autism spectrum disorders, obsessive-compulsive disorder, personality disorder, anorexia, self harm, PTSD, previous abuse ∗ Catastrophisation ∗ Psychological stress makes pain worse & vice-versa Guidelines for management of chronic pain Scottish Intercollegiate Guidelines Network Evidence based recs https://www.sign.ac.uk/assets/sign136_2019.pdf Task force review Gaps & recs U.S. Department of Health and Human Services (2019, May). Pain Management Best Practices Inter-Agency Task U.S. Department of Health and Human Services Force Report: Updates, Gaps, Inconsistencies, and Recommendations. Retrieved from U. S. Department of Health and Human Services website: https://www.hhs.gov/ash/advisory- committees/pain/reports/index.html Guidelines Neuropathic Pain ∗ International Association for the Study of Pain ∗ Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162–73. ∗ Haanpaa M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011;152:14–27. ∗ European Federation of Neurological Societies (EFNS) ∗ Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol.2010;17:1113. ∗ Cruccu G, Sommer C, Anand P, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol. 2010;17:1010–8. ∗ National Institute for Health and CareExcellence ∗ National Institute for Health and Care Excellence (NICE). Neuropathic pain: the pharmacological management of neuropathic pain in adults innon-specialist settings. 2013. ∗ Canadian Pain Society (CPS) ∗ Moulin D, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19:328–35. Fibromyalgia: European League Against Rheumatism (EULAR) 2008; revised 2016 American Pain Society (APS) 2005 German (Association of the Scientific Medical Societies, AWMF) 2012 Israeli Canadian Pain Society (CPS) 2013 Chronic pain Interventional Rx Controversies and challenges in fibromyalgia: a review and a proposal. Cohen H. Ther Adv Musculoskelet Dis. 2017 May;9(5):115-127. doi: 10.1177/1759720X17699199. Epub 2017 Mar 26. Review. Why don’t drugs seem to work? Causes of chronic pain It is suggested that: • Multiple mechanisms involving various regions of entire neuraxis • Pathophysiology may vary from one patient to another Drug treatment ∗ NSAIDs – inflammatory pain ∗ Neuromodulatory medication ∗ Tricyclic antidepressants eg. amitriptyline – increase serotonin +/- noradrenaline, ∗ Gabapentin, pregabalin – increase GABA ∗ SNRI eg. Duloxetine – increase S, NA ∗ Ketamine, memantine – affect NMDA receptor ∗ Opioids ∗ Capsaicin – TRVP1 ∗ Anti-nerve growth factor Ab biologic drugs (tanezumab) ∗ Cannabis & derivatives? ∗ BIA 10-2474 - FAA inhibitor – French drug trial 2016 – 1 death, 5 hospitalised. ∗ IF IT DOES NOT WORK OR CAUSES SIDE EFFECTS, STOP IT Medication ∗ WHO pain ladder not appropriate – opiate rung ∗ Where are opiates are used – caution, monitoring, pain clinic involvement http://www.sign.ac.uk/guidelines/fulltext/136/section5.html Guidelines summary ∗ Not much difference between Chronic pain, FMS and NeuPain guidelines ∗ Non-NeuPain – more use of NSAIDs, paracetamol, weak opioids, topical NSAIDs ∗ (Cruccu) “There is a broad agreement among the guidelines on pharmacological treatment of neuropathic pain” ∗ Three drug classes have received strong recommendations for first-line therapy in all guidelines: ∗ tricyclic antidepressants, particularly amitriptyline ∗ serotonin-norepinephrine reuptake inhibitors (SNRIs) such as duloxetine ∗ Gabapentinoids
Load more

Recommended publications
  • Print PDF Opens in a New Window
    CADTH ISSUES IN EMERGING HEALTH TECHNOLOGIES Informing Decisions About New Health Technologies Issue July 173 2018 Monoclonal Antibodies for Osteoarthritis of the Hip or Knee Image courtesy of iStock CADTH ISSUES IN EMERGING HEALTH TECHNOLOGIES 1 Authors: Sirjana Pant, Ke Xin Li, Melissa Severn Cite As: Monoclonal Antibodies for Osteoarthritis of the Hip or Knee. Ottawa: CADTH; 2018. (CADTH issues in emerging health technologies; issue 173). Acknowledgments: CADTH would like to acknowledge the contribution of Dr. Tom Appleton, MD, PhD, FRCPC, Assistant Professor, Rheumatologist; Department of Medicine, Department of Physiology and Pharmacology, The University of Western Ontario; Clinician Scientist, Lawson Health Research Institute; The Rheumatology Centre, St. Joseph’s Health Care London; for his review of the draft version of this bulletin. ISSN: 1488-6324 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy- makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • February 2021 EPS Pipeline Report
    Pipeline Report February 2021 Pipeline Report February 2021 © 2021 Envolve. All rights reserved. Page 1 This quarterly at-a-glance publication is developed by our Clinical Pharmacy Drug Information team to increase your understanding of the drug pipeline, Table of Contents ensuring you’re equipped with insights to prepare for shifts in pharmacy benefit management. In this issue, you’ll learn more about key themes and notable drugs referenced in the following points. COVID-19 1 > Veklury is currently the only agent that is FDA-approved for the treatment of COVID-19. Three additional therapeutics and two vaccines have been granted Emergency Use Authorization (EUA), and at least three more vaccines are Recent Specialty Drug Approvals1 4 expected to receive an EUA in the relatively near future. > The previous quarter noted the approval of several breakthrough therapies for rare or ultra-rare conditions, which previously had no available FDA-approved Recent Non-Specialty Drug Approvals 9 treatments — Zokinvy for Hutchinson-Gilford progeria syndrome and progeroid laminopathies, Oxlumo for primary hyperoxaluria type 1, and Imcivree for genetically mediated obesity. Upcoming Specialty Products 10 > Other notable approvals include: Lupkynis — the first oral therapy approved for lupus nephritis; Orladeyo — the first oral therapy approved as prophylaxis of hereditary angioedema attacks;Cabenuva – the first long-acting injectable antiretroviral therapy intended as maintenance treatment of HIV; and Breyanzi — Upcoming Non-Specialty Products 18 the
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • Targeting Nerve Growth Factor for Pain Management in Osteoarthritis- Clinical Efficacy and Safety
    UC Davis UC Davis Previously Published Works Title Targeting Nerve Growth Factor for Pain Management in Osteoarthritis- Clinical Efficacy and Safety. Permalink https://escholarship.org/uc/item/70d2q815 Journal Rheumatic diseases clinics of North America, 47(2) ISSN 0889-857X Authors Dietz, Brett W Nakamura, Mary C Bell, Matthew T et al. Publication Date 2021-05-01 DOI 10.1016/j.rdc.2020.12.003 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Targeting Nerve Growth Factor for Pain Management in Osteoarthritis—Clinical Efficacy and Safety a, b Brett W. Dietz, MD *, Mary C. Nakamura, MD , c d Matthew T. Bell, BS , Nancy E. Lane, MD KEYWORDS NGF Anti-NGF Osteoarthritis Pain Nerve growth factor Review KEY POINTS Nerve growth factor plays a key role in pain hypersensitization in osteoarthritis. Inhibition of nerve growth factor is effective at reducing pain and improving physical func- tion from osteoarthritis of the hip or knee. Use of these agents is complicated by adverse joint safety events, notably rapidly pro- gressive osteoarthritis and an increased need for joint replacements. The mechanism driving these joint safety events remains poorly understood and is an important area for further study. BACKGROUND Osteoarthritis (OA) is a leading cause of global disability,1 affecting as many as 250 million people worldwide.2 Estimates of the direct and indirect economic costs of OA range from 1% to 2.5% of the gross domestic product in the United States, Can- ada, France, the United Kingdom, and Australia.3 Guidelines for management of OA generally agree on nonpharmacologic management with exercise, weight loss, educa- tion and self-management, and hip or knee joint replacement in appropriate patients.
    [Show full text]
  • Clinical Protocol a Phase 3 Randomized, Double-Blind
    Tanezumab A4091063 Final Protocol Amendment 2, 14 September 2017 CLINICAL PROTOCOL A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG-TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN JAPANESE ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN Compound: PF-04383119 Compound Name: Tanezumab United States (US) Investigational New NA Drug (IND) Number: European Clinical Trials Database NA (EudraCT) Number: Protocol Number: A4091063 Phase: 3 This document contains confidential information belonging to Pfizer. Except as otherwise agreed to in writing, by accepting or reviewing this document, you agree to hold this information in confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer must be promptly notified. PFIZER CONFIDENTIAL Page 1 Tanezumab A4091063 Final Protocol Amendment 2, 14 September 2017 Document History Document Version Date Summary of Changes Amendment 2 14 September 2017 Considering study feasibility, number of subjects with 1-year exposure and capability of safety evaluation with the data from this study, the target sample size was changed to approximately 200 (170-220) subjects and Section 9.1 and associated texts throughout the protocol were updated. Additionally, it is acceptable to randomize more than 220 subjects from the safety perspective. Per change of target sample size, analysis of serum tanezumab and NGF levels at Weeks 2 and 4 were changed to be conducted for part of subjects (i.e. approximately 30% of subjects randomized at selected sites) to all subjects randomized.
    [Show full text]
  • Wednesday, June 12, 2019 4:00Pm
    Wednesday, June 12, 2019 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Melissa Abbott, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – June 12, 2019 DATE: June 5, 2019 Note: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the June meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/Use of Angiotensin Converting Enzyme Inhibitor (ACEI)/ Angiotensin Receptor Blocker (ARB) Therapy in Patients with Diabetes and Hypertension (HTN) Mailing Update – Appendix B Action Item – Vote to Prior Authorize Aldurazyme® (Laronidase) and Naglazyme® (Galsulfase) – Appendix C Action Item – Vote to Prior Authorize Plenvu® [Polyethylene Glycol (PEG)-3350/Sodium Ascorbate/Sodium Sulfate/Ascorbic Acid/Sodium Chloride/Potassium Chloride] – Appendix D Action Item – Vote to Prior Authorize Consensi® (Amlodipine/Celecoxib) and Kapspargo™ Sprinkle [Metoprolol Succinate Extended-Release (ER)] – Appendix E Action Item – Vote to Update the Prior Authorization Criteria For H.P. Acthar® Gel (Repository Corticotropin Injection) – Appendix F Action Item – Vote to Prior Authorize Fulphila® (Pegfilgrastim-jmdb), Nivestym™ (Filgrastim-aafi),
    [Show full text]
  • Therapeutic Proteins and Their Use in Posterior Eye Segment Diseases
    Division of Pharmaceutical Biosciences Faculty of Pharmacy University of Helsinki Finland Therapeutic proteins and their use in posterior eye segment diseases Jaakko Itkonen DOCTORAL THESIS to be presented for public examination, with the permission of the Faculty of Pharmacy of the University of Helsinki, in Lecture Hall 3 (A108), Metsätieteiden talo (Latokartanonkaari 7), on the 3rd of October, 2020, at 12 o’clock. Helsinki 2020 Supervisors: Professor Arto Urtti, Ph.D. (Pharm.) Division of Pharmaceutical Biosciences Faculty of Pharmacy University of Helsinki Finland Marco G. Casteleijn, Ph.D. Industrial Biotechnology, Protein production VTT Technical Research Centre of Finland Ltd. Espoo, Finland Reviewers: Research Professor Emeritus Hans Söderlund, Ph.D. Biotechnology, Process technology VTT Technical Research Centre of Finland Ltd. Espoo, Finland Adjunct Professor Soile Nymark, Ph.D. Faculty of Medicine and Health Technology Tampere University Finland Opponent: Principal Scientist Robert F. Kelley, Ph.D. Genentech, Inc. San Francisco, USA The Faculty of Pharmacy uses the Urkund system (plagiarism recognition) to examine all doctoral dissertations. © Jaakko Itkonen 2020 ISBN 978-951-51-6289-2 (print) ISBN 978-951-51-6290-8 (PDF; online: http://ethesis.helsinki.fi/) Dissertationes Scholae Doctoralis ad Sanitatem Investigandam Universitatis Helsinkiensis ISSN 2342-3161 (print) 2342-317X (online) Unigrafia Oy Helsinki 2020 Äideille I Abstract Since their introduction in the late 20th century, therapeutic proteins have become an irreplaceable class of pharmaceuticals and are today used to treat a wide variety of diseases ranging from arthritis, diabetes, and various cancers to more recently, for example, asthma and migraine. In ophthalmology, the treatment of certain neurodegenerative diseases of the retina, such as age-related macular degeneration and diabetic retinopathy, has been revolutionized by therapeutic proteins that combat the pathological growth of abnormal blood vessels in the retina.
    [Show full text]
  • Roche CEO: Novel Gene Therapies Justify New Payment Models
    26 April 2019 No. 3952 Scripscrip.pharmaintelligence.informa.com Pharma intelligence | informa “Gene therapies have the potential to actually cure disease, and consequently the value of that to the healthcare system can be huge, not only for the patients who suffer from that disease but also from a cost perspective because you save a lot of follow-on costs and I would add, go beyond that from a societal perspective, if those patients are really cured, as they can go back to work and make their contribu- tions paying taxes, social contributions, etc.,” Schwan said. “Having said that, what is special with gene therapies is that you get this up-front treatment and that can in- deed be a one-off burden for a health- care system and I believe we will need to find innovative approaches and new pricing models.” The issue will become more relevant once Roche takes control of Philadelphia- Roche CEO: Novel Gene Therapies based Spark Therapeutics, which it has offered to buy for $4.8bn and which, after Justify New Payment Models a regulatory delay, is expected to close in the first-half of the year. STEN STOVALL [email protected] Roche views Spark as a valuable prize, largely due to its gene therapy for he up-front, one-off payment mod- systems and society as a whole. He also a rare type of blindness which the US el for patients being treated with said the advent of gene therapy, which FDA approved in 2017, known as Lux- Trevolutionary gene therapies isn’t introduces new genetic material into a turna (voretigene neparvovec).
    [Show full text]
  • Ep 3321281 A1
    (19) TZZ¥¥ _ __T (11) EP 3 321 281 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 16.05.2018 Bulletin 2018/20 C07K 14/79 (2006.01) A61K 38/40 (2006.01) A61K 38/00 (2006.01) A61K 38/17 (2006.01) (2006.01) (2006.01) (21) Application number: 17192980.5 A61K 39/395 A61K 39/44 C07K 16/18 (2006.01) (22) Date of filing: 03.08.2012 (84) Designated Contracting States: • TIAN, Mei Mei AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Coquitlam, BC V3J 7E6 (CA) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • VITALIS, Timothy PL PT RO RS SE SI SK SM TR Vancouver, BC V6Z 2N1 (CA) (30) Priority: 05.08.2011 US 201161515792 P (74) Representative: Gowshall, Jonathan Vallance Forresters IP LLP (62) Document number(s) of the earlier application(s) in Skygarden accordance with Art. 76 EPC: Erika-Mann-Strasse 11 12746240.6 / 2 739 649 80636 München (DE) (71) Applicant: biOasis Technologies Inc Remarks: Richmond BC V6X 2W8 (CA) •This application was filed on 25.09.2017 as a divisional application to the application mentioned (72) Inventors: under INID code 62. • JEFFERIES, Wilfred •Claims filed after the date of receipt of the divisional South Surrey, BC V4A 2V5 (CA) application (Rule 68(4) EPC). (54) P97 FRAGMENTS WITH TRANSFER ACTIVITY (57) The present invention is related to fragments of duction of the melanotransferrin fragment conjugated to human melanotransferrin (p97). In particular, this inven- a therapeutic or diagnostic agent to a subject.
    [Show full text]
  • A Patient's Guide to Living with Osteoarthritis
    Raising the Voice of Patients A PATIENT’S GUIDE TO LIVING WITH OSTEOARTHRITIS First Edition ©2017 GLOBAL HEALTHY LIVING FOUNDATION, INC. Welcome to the first edition of CreakyJoints’ patient guidelines for osteoarthritis (OA). It is designed to help raise your voice with the decision-makers you’ll encounter while living with this condition. This guide is the first of its kind, and it is developed by leading experts including doctors, patients, and other healthcare providers. It’s meant to serve as a roadmap to help you navigate your OA, while helping you get what you want, need and deserve from your treatment journey. It offers detailed, accessible explanations of symptoms and what causes them, treatment plans, treatment options, integrated medicines and therapies, diet and exercise, as well as how to talk to your insurance company, and your family and friends about your disease and the ways in which it impacts your life. This first edition has been edited by leading doctors and healthcare experts, and will be updated and improved regularly as new research, information, and treatments on OA become available. p The information in these guidelines should never replace the information and advice from your treating physician. It is meant to inform the discussion that you have with healthcare professionals, as well as others who play a role in your care and well-being. Table of Contents 2 PART ONE Patient Charter 4 PART TWO Introduction 6 PART THREE Treatment Guidelines 9 PART FOUR Osteoarthritis Overview 11 PART FIVE Monitoring 14 PART SIX
    [Show full text]
  • Asp6294 Non-Confidential Summary Disclaimer 2
    ASP6294 NON-CONFIDENTIAL SUMMARY DISCLAIMER 2 This material includes forward-looking statements based on assumptions and beliefs in light of information currently available to the Astellas and subject to significant risks and uncertainties. This material contains information on pharmaceuticals (including compounds in research or under development) and other matters. Notwithstanding the foregoing, Astellas makes no representations, warranties, assurances or guarantees of any kind or nature whatsoever, whether expressed or implied, regarding the information in the materials (including, without limitation, no representations, warranties, assurances or guarantees as to the accuracy, sufficiency or completeness of any information, as to whether Astellas has rights to any such information or pharmaceuticals/compounds, as to whether any third party has or does not have any rights to any of such information or pharmaceuticals/compounds, as to the safety, efficacy, or effectiveness of any preparations described in this material, as to the regulatory status of or potential for regulatory agency action regarding any pharmaceuticals/ compounds described in this material, or as to any uses, including unapproved uses, of any such preparations in any fashion). This material does not provide medical advice of any kind. Astellas undertakes no obligation or duty to change, remove, add, clarify, correct or update any information in the materials at any time. ASP6294 NON-CONFIDENTIAL SUMMARY -- Version dated October 23, 2020 ASP6294: EXECUTIVE SUMMARY 3 •
    [Show full text]